ClinicalTrials.gg
CompletedNCT05067335Updated Sep 28, 2026Results posted

A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis

A Phase 3 interventional study of Romosozumab and Placebo in Osteoporosis, sponsored by UCB Biopharma SRL. Completed at 30 sites in China. Open to female participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Updated Sep 28, 2026Results publication added1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
327
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing romosozumab in Osteoporosis — 5 open to participants now, 8 under way, none of them phase 3. romosozumab · Osteoporosis.

Enrollment
3rd of 20
327 · median 80
Started
2021
with 4 others
Phase 3
5 of 20
none open now
Registered
11th of 20
by date
Lead sponsor
1 of 20
UCB Biopharma SRL

Among the 20 studies testing romosozumab in Osteoporosis, this one is the 3rd largest by enrollment, is one of 5 that started in 2021, is one of 5 in phase 3, and was the 11th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

5 of the 20 studies testing romosozumab in Osteoporosis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romosozumab

romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 55 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing romosozumab in Osteoporosis, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the effect of treatment with romosozumab for 6 months compared with placebo on the percent changes in bone mineral density (BMD) at the lumbar spine, at the total hip and femoral neck in postmenopausal Chinese women with osteoporosis.

03

Conditions studied

  • Osteoporosis

Browse trials for

Keywords

  • Osteoporosis
  • Phase 3
  • Chinese Patients
  • Romosozumab
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is considered reliable and capable of adhering to the protocol, visit schedule, and medication intake according to the judgment of the investigator
  • Subject is an ambulatory Chinese women, 55 to 90 years of age (inclusive) at the time of Screening. Postmenopause is defined as no spontaneous vaginal bleeding or spotting for 12 or more consecutive months prior to Screening
  • Subject has a bone mineral density (BMD) T-score ≤-2.50 at the lumbar spine, total hip, or femoral neck, as assessed by the central imaging vendor at the time of Screening based on DXA scans, and using data for Caucasian women from the National Health and Nutritional Examination Survey (NHANES, 1998)
  • Subject must have at least 1 of following independent risk factors for fracture:

    • History of fragility fracture (except hip fracture, a severe vertebral fracture or more than 2 moderate vertebral fractures)
    • Parental history of hip fracture
    • Low body weight ( ≤19kg/m2)
    • Elderly (age ≥ 65 years)
    • Current smoker
  • Subject has at least 2 vertebrae in the L1 to L4 region and at least 1 hip that are evaluable by dual-energy x-ray absorptiometry (DXA), as assessed by the central imaging vendor

Exclusion criteria

Exclusion Criteria:

  • Subject has a BMD T-score of ≤-3.50 at the total hip or femoral neck, as assessed by the central imaging vendor at the time of Screening based on DXA scans, and using data for Caucasian women from NHANES 1998
  • Subject has a known history of hip fracture
  • Subject has any severe (SQ3) or more than 2 moderate (SQ2) vertebral fractures, as assessed by the central imaging vendor based on the lateral spine x-ray at Screening
  • Subject has a history of myocardial infarction (MI)
  • Subject has a history of stroke
  • Subject has a vitamin D insufficiency, defined as 25 (OH) vitamin D levels \<20 ng/mL, as assessed by the central laboratory at Screening. Vitamin D repletion will be permitted and the subject may be retested once within the Screening Period
  • Subject has used oral bisphosphonates:

    • Any doses received within 3 months prior to randomization
    • More than 1 month of cumulative use between 3 and 12 months prior to randomization
    • More than 3 years of cumulative use, unless the last dose was received ≥5 years prior to randomization
  • Subject has used intravenous (iv) bisphosphonates:

    • zoledronic acid

      • Any doses received within 3 years prior to randomization
      • More than 1 dose received within 5 years prior to randomization
    • iv ibandronate, iv pamidronate, or iv alendronate (ALN)

      • Any doses received within 12 months prior to randomization
      • More than 3 years of cumulative use, unless the last dose was received ≥5 years prior to randomization
  • Subject has used denosumab or any cathepsin K inhibitor:

    ● Any doses received within 18 months prior to randomization

  • Subject has used tibolone, cinacalcet, or calcitonin:

    • Any doses received within 3 months prior to randomization
  • Subject has used teriparatide (TPTD) or any parathyroid hormone (PTH) derivative:

    • Any doses received within 3 months prior to randomization
    • More than 1 month of cumulative use between 3 and 12 months prior to randomization
  • Subject has used systemic oral or transdermal estrogen or selective estrogen receptor modulators (SERMs):

    ● More than 1 month of cumulative use within 6 months prior to randomization

  • Subject has used strontium ranelate or fluoride:

    ● More than 1 month of cumulative use within 5 years prior to randomization

  • Subject has used hormonal ablation therapy:

    ● More than 1 month of cumulative use within 6 months prior to randomization

  • Subject has used systemic glucocorticosteroids:

    ● ≥5mg prednisone equivalent per day for more than 14 days within 3 months prior to randomization

  • Subject has a history of osteonecrosis of the jaw (ONJ) or atypical femoral fracture (AFF)
  • Subject has evidence of any of the following:

    1. Current, uncontrolled hyper- or hypothyroidism. Uncontrolled hyperthyroidism is defined as thyroid-stimulating hormone (TSH) and thyroxine (T4) outside of the normal range. Uncontrolled hypothyroidism is defined as TSH >10
    2. Current, uncontrolled hyperparathyroidism or history of hypoparathyroidism. Uncontrolled hyperparathyroidism is defined as PTH outside the normal range in subjects with concurrent hypercalcemia or PTH values >20 % above (ULN) in normocalcemic subjects
    3. Current hypercalcemia or hypocalcemia, defined as albumin-adjusted serum calcium outside the normal range, as assessed by the central laboratory at the time of Screening. Albumin-adjusted serum calcium levels may be retested once in case of an elevated albumin-adjusted serum calcium level within 1.1xULN of the laboratory's reference ranges
    4. Subject has ≥3xULN of any of the following: (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >ULN total (≥1.5xULN total bilirubin if known Gilbert's syndrome). If subject has elevations only in total bilirubin that are >ULN and \<1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (ie, direct bilirubin \<35 %)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
327 participants (actual)

Study arms

  • Experimental
    Romosozumab

    Subjects randomized to this arm will receive romosozumab during all treatment Periods.

    Drug: Romosozumab

  • Placebo comparator
    Placebo

    Subjects randomized to this arm will receive placebo during the Double-Blind-Placebo controlled Period and romosozumab during the Open-Label treatment Period

    Drug: Romosozumab · Drug: Placebo

Interventions

  • Subjects will receive romosozumab in a specified sequence during the treatment Period.

  • DrugPlacebo

    Subjects will receive Placebo in a specified sequence during the treatment Period.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine to the End of Double-Blind Period

    Percent change from baseline in BMD at the lumbar spine was assessed by dual-energy x-ray absorptiometry (DXA) at 6 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the last observation carried forward (LOCF) approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach. LSM = least square mean.

    Time frame: From Baseline (Day 1) to the end of the Double-blind Period (Month 6)

  2. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a IMP, whether or not related to the IMP. TEAEs are defined as all AEs started on or worsened in severity on or after the date of receiving first dose of IMP and before or on the end of study (EOS) date.

    Time frame: From Baseline to the end of the Double-blind Period (Month 6)

  3. Percentage of Participants With Treatment-emergent Adverse Events for Romosozumab During Overall Period

    An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with use of a IMP, whether or not related to IMP. TEAEs are defined as all AEs started on or worsened in severity on or after date of receiving first dose of IMP and before or on EOS date except lipid-type AEs starting on date of first dose of IMP and not worsening (and not deemed IMP related by the investigator). As pre-specified in Protocol and SAP, TEAEs were assessed and reported for 6 months for participants in placebo/romosozumab arm (Open-label Period) and for a total of 12 months for participants in romosozumab/romosozumab arm (Double-blind Period + Open-label Period combined) + 3 months of Safety follow-up for both arms (Up to Month 15) during overall period.

    Time frame: From Month 7 up to Month 12 (Placebo/Romo) and From Day 1 up to Month 12 (Romo/Romo) + 3-month SFU (up to Month 15)

Secondary outcomes

  1. Percent Change From Baseline in Bone Mineral Density at the Total Hip to the End of Double-Blind Period

    Percent change from baseline in BMD at the total hip was assessed by DXA at 6 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach.

    Time frame: From Baseline to the end of the Double-blind Period (Month 6)

  2. Percent Change From Baseline in Bone Mineral Density at the Femoral Neck to the End of the Double-Blind Period

    Percent change from baseline in BMD at the femoral neck was assessed by DXA at 6 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach.

    Time frame: From Baseline to the end of the Double-blind Period (Month 6)

  3. Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12

    Percent change from Baseline in BMD at the lumbar spine was assessed by DXA at 12 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach. For Placebo/Romosozumab Treatment group, only the post Month 6 value was used for imputation for Open-label Period, the values in the Double-blind Period were not carried forward into the Open-label Period.

    Time frame: Baseline, Month 12

  4. Percent Change From Baseline in Bone Mineral Density at the Total Hip at Month 12

    Percent change from Baseline in BMD at the total hip was assessed by DXA at 12 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach. For Placebo/Romosozumab Treatment group, only the post Month 6 value was used for imputation for Open-label Period, the values in the Double-blind Period were not carried forward into the Open-label Period.

    Time frame: Baseline, Month 12

  5. Percent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 12

    Percent change from Baseline in BMD at the femoral neck was assessed by DXA at 12 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach. For Placebo/Romosozumab Treatment group, only the post Month 6 value was used for imputation for Open-label Period, the values in the Double-blind Period were not carried forward into the Open-label Period.

    Time frame: Baseline, Month 12

07

Results

Posted Dec 5, 2024

Participant flow

The study started to enroll participants in October 2021 and concluded in November 2023.

Double-blind Period: Day 1 - Month 6
Participant flow — Double-blind Period: Day 1 - Month 6
MilestonePlaceboRomosozumabPlacebo/RomosozumabRomosozumab/Romosozumab
Started10921800
Completed10020400
Not completed91400
Withdrew: Adverse event1200
Withdrew: Protocol violation1100
Withdrew: Withdrawal by subject61000
Withdrew: Patient voluntary withdrawal1000
Withdrew: The patient withdrew early due to their own reasons0100
Open-label Period: Month 7 - 12
Participant flow — Open-label Period: Month 7 - 12
MilestonePlaceboRomosozumabPlacebo/RomosozumabRomosozumab/Romosozumab
Started0099204
Completed0093199
Not completed0065
Withdrew: Adverse event0032
Withdrew: Lost to follow-up0010
Withdrew: Withdrawal by subject0003
Withdrew: Subject was unable to comply with study procedures due to prolonged withdrawal from medication0010
Withdrew: Did not receive open-label imp at month 6 and then discontinued0010

Outcome measures

PrimaryPercent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine to the End of Double-Blind Period

Percent change from baseline in BMD at the lumbar spine was assessed by dual-energy x-ray absorptiometry (DXA) at 6 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the last observation carried forward (LOCF) approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach. LSM = least square mean.

Time frame:
From Baseline (Day 1) to the end of the Double-blind Period (Month 6)
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine to the End of Double-Blind Period
percent changePlaceboRomosozumab
Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine to the End of Double-Blind Period0.44 ± 0.4429.81 ± 0.323
Statistical analysis
  • Placebo vs Romosozumab · ANCOVA · p = <0.001 · Difference in lsm(romosozumab - placebo): 9.37 · 95% CI 8.34 to 10.39
PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period

An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a IMP, whether or not related to the IMP. TEAEs are defined as all AEs started on or worsened in severity on or after the date of receiving first dose of IMP and before or on the end of study (EOS) date.

Time frame:
From Baseline to the end of the Double-blind Period (Month 6)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period
percentage of participantsPlaceboRomosozumab
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period70.672.9
PrimaryPercentage of Participants With Treatment-emergent Adverse Events for Romosozumab During Overall Period

An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with use of a IMP, whether or not related to IMP. TEAEs are defined as all AEs started on or worsened in severity on or after date of receiving first dose of IMP and before or on EOS date except lipid-type AEs starting on date of first dose of IMP and not worsening (and not deemed IMP related by the investigator). As pre-specified in Protocol and SAP, TEAEs were assessed and reported for 6 months for participants in placebo/romosozumab arm (Open-label Period) and for a total of 12 months for participants in romosozumab/romosozumab arm (Double-blind Period + Open-label Period combined) + 3 months of Safety follow-up for both arms (Up to Month 15) during overall period.

Time frame:
From Month 7 up to Month 12 (Placebo/Romo) and From Day 1 up to Month 12 (Romo/Romo) + 3-month SFU (up to Month 15)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events for Romosozumab During Overall Period
percentage of participantsPlacebo/RomosozumabRomosozumab/Romosozumab Overall
Percentage of Participants With Treatment-emergent Adverse Events for Romosozumab During Overall Period80.688.1
SecondaryPercent Change From Baseline in Bone Mineral Density at the Total Hip to the End of Double-Blind Period

Percent change from baseline in BMD at the total hip was assessed by DXA at 6 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach.

Time frame:
From Baseline to the end of the Double-blind Period (Month 6)
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density at the Total Hip to the End of Double-Blind Period
percent changePlaceboRomosozumab
Percent Change From Baseline in Bone Mineral Density at the Total Hip to the End of Double-Blind Period0.07 ± 0.2852.93 ± 0.206
Statistical analysis
  • Placebo vs Romosozumab · ANCOVA · p = <0.001 · Difference in lsm(romosozumab - placebo): 2.86 · 95% CI 2.18 to 3.54
SecondaryPercent Change From Baseline in Bone Mineral Density at the Femoral Neck to the End of the Double-Blind Period

Percent change from baseline in BMD at the femoral neck was assessed by DXA at 6 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach.

Time frame:
From Baseline to the end of the Double-blind Period (Month 6)
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density at the Femoral Neck to the End of the Double-Blind Period
percent changePlaceboRomosozumab
Percent Change From Baseline in Bone Mineral Density at the Femoral Neck to the End of the Double-Blind Period-0.15 ± 0.4063.33 ± 0.347
Statistical analysis
  • Placebo vs Romosozumab · ANCOVA · p = <0.001 · Difference in lsm(romosozumab - placebo): 3.48 · 95% CI 2.58 to 4.38
SecondaryPercent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12

Percent change from Baseline in BMD at the lumbar spine was assessed by DXA at 12 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach. For Placebo/Romosozumab Treatment group, only the post Month 6 value was used for imputation for Open-label Period, the values in the Double-blind Period were not carried forward into the Open-label Period.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12
percent changePlacebo/Romosozumab OverallRomosozumab/Romosozumab Overall
Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 128.80 ± 0.55413.04 ± 0.389
SecondaryPercent Change From Baseline in Bone Mineral Density at the Total Hip at Month 12

Percent change from Baseline in BMD at the total hip was assessed by DXA at 12 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach. For Placebo/Romosozumab Treatment group, only the post Month 6 value was used for imputation for Open-label Period, the values in the Double-blind Period were not carried forward into the Open-label Period.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density at the Total Hip at Month 12
percent changePlacebo/Romosozumab OverallRomosozumab/Romosozumab Overall
Percent Change From Baseline in Bone Mineral Density at the Total Hip at Month 121.83 ± 0.3064.22 ± 0.216
SecondaryPercent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 12

Percent change from Baseline in BMD at the femoral neck was assessed by DXA at 12 months. Missing postbaseline BMD other than due to COVID-19 were imputed using the LOCF approach. Missing or out of window (exceed 70 days since previous IMP) post-baseline DXA BMD due to COVID-19 were set to missing and imputed by multiple imputation under missing at random approach. For Placebo/Romosozumab Treatment group, only the post Month 6 value was used for imputation for Open-label Period, the values in the Double-blind Period were not carried forward into the Open-label Period.

Time frame:
Baseline, Month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 12
percent changePlacebo/Romosozumab OverallRomosozumab/Romosozumab Overall
Percent Change From Baseline in Bone Mineral Density at the Femoral Neck at Month 121.87 ± 0.4414.66 ± 0.371

Adverse events

Collected over From Baseline to Safety Follow Up (up to Month 15). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/109 (0%)5/109 (4.6%)25/109 (22.9%)
Romosozumab0/218 (0%)8/218 (3.7%)59/218 (27.1%)
Placebo/Romosozumab0/98 (0%)9/98 (9.2%)59/98 (60.2%)
Romosozumab/Romosozumab Overall1/218 (0.5%)25/218 (11.5%)155/218 (71.1%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventPlaceboRomosozumabPlacebo/RomosozumabRomosozumab/Romosozumab Overall
AppendicitisInfections and infestations0/1090/2181/980/218
Upper respiratory tract infectionInfections and infestations0/1090/2181/980/218
Femoral neck fractureInjury, poisoning and procedural complications0/1090/2181/980/218
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/1090/2181/981/218
Adenocarcinoma gastricNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1090/2181/980/218
Cerebrovascular insufficiencyNervous system disorders0/1090/2181/982/218
Diabetic neuropathyNervous system disorders0/1090/2181/980/218
Lacunar infarctionNervous system disorders0/1090/2181/980/218
Vertebrobasilar insufficiencyNervous system disorders0/1090/2181/980/218
Calculus urinaryRenal and urinary disorders0/1090/2181/980/218
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlaceboRomosozumabPlacebo/RomosozumabRomosozumab/Romosozumab Overall
COVID-19Infections and infestations12/10915/21822/9849/218
Suspected COVID-19Infections and infestations4/10911/21814/9843/218
Upper respiratory tract infectionInfections and infestations5/10913/2186/9830/218
CoughRespiratory, thoracic and mediastinal disorders1/1096/21812/9819/218
ArthralgiaMusculoskeletal and connective tissue disorders5/10911/2181/9822/218
Injection site reactionGeneral disorders1/10919/2186/9820/218
PyrexiaGeneral disorders1/1093/2186/9816/218
Back painMusculoskeletal and connective tissue disorders3/1098/2181/9816/218
SARS-CoV-2 test positiveInvestigations1/1093/2183/9812/218
HyperlipidaemiaMetabolism and nutrition disorders2/1099/2184/9812/218

Baseline characteristics

Baseline Characteristics refer to the RS which consisted of study participants who were randomized into this study.

Age, Continuous
Age, Continuous(Years)PlaceboRomosozumabTotal
Mean67.3 ± 6.167.0 ± 5.767.1 ± 5.8
Age, Customized
Age, Customized(Participants)PlaceboRomosozumabTotal
18 - <65 yrs316394
65 - <85 yrs76154230
>=85 yrs213
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRomosozumabTotal
Female109218327
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRomosozumabTotal
Asian109218327
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboRomosozumabTotal
Not Hispanic or Latino109218327
08

Study locations

30 sites
  • Op0002 20040
    Beijing, China
  • Op0002 20115
    Beijing, China
  • Op0002 20125
    Beijing, China
  • Op0002 20127
    Beijing, China
  • Op0002 20128
    Beijing, China
  • Op0002 20130
    Beijing, China
  • Op0002 20131
    Beijing, China
  • Op0002 20157
    Beijing, China
  • Op0002 20021
    Chengdu, China
  • Op0002 20133
    Chengdu, China
  • Op0002 20137
    Chengdu, China
  • Op0002 20205
    Foshan, China
  • Op0002 20117
    Guangzhou, China
  • Op0002 20124
    Guangzhou, China
  • Op0002 20209
    Nanchang, China
  • Op0002 20135
    Nanjing, China
  • Op0002 20202
    Pingxiang, China
  • Op0002 20199
    Rui’an, China
  • Op0002 20116
    Shanghai, China
  • Op0002 20118
    Shanghai, China
  • Op0002 20121
    Shanghai, China
  • Op0002 20123
    Shanghai, China
  • Op0002 20129
    Shanghai, China
  • Op0002 20119
    Suzhou, China
  • Op0002 20204
    Suzhou, China
  • Op0002 20122
    Tianjin, China
  • Op0002 20136
    Tianjin, China
  • Op0002 20120
    Wuhan, China
  • Op0002 20134
    Yueyang, China
  • Op0002 20132
    Zhengzhou, China
09

References and documents

Publications

  • Zhenlin Z, Qingyun X, Decai C, Aijun C, Yanan H, Mei Z, Xu C, Hua L, Youjia X, Qun C, Huilin Y, Xiaoyan X, Yujie L, Xuan D, Jun J, LingLing G, Theresa RJ, Lars B, Weibo X. Romosozumab increases bone mineral density in postmenopausal Chinese women with osteoporosis: A randomised phase three study. J Orthop Translat. 2026 Jun 3;59:101135. doi: 10.1016/j.jot.2026.101135. eCollection 2026 Jul. PubMed 42282279 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Nov 2023, 24 months.

Results were first posted in Dec 2024, 1 year after primary completion.

Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 24 months is close to that.

Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2021
First posted
Oct 5, 2021
StartActual
Oct 21, 2021
Primary completionActual
Nov 9, 2023
CompletionActual
Nov 9, 2023
Results first posted
Dec 5, 2024
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Op0002 20199 · Rui’an, China
Show 1 removed
  • Op0002 20199 · Rui'an, China
Sep 28, 2026
Publications
Results publication added: Zhenlin Z, Qingyun X, Decai C, Aijun C, Yanan H, Mei Z, Xu C, Hua L, Youjia X, Qun C, Huilin Y, Xiaoyan X, Yujie L, Xuan D, Jun J, LingLing G, Theresa RJ, Lars… PubMed 42282279 ↗
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Publications Results publication added: Zhenlin Z, Qingyun X, Decai C, Aijun C, Yanan H, Mei Z, Xu C, Hua L, Youjia X, Qun C, Huilin Y, Xiaoyan X, Yujie L, Xuan D, Jun J, LingLing G, Theresa RJ, Lars… PubMed 42282279 ↗
    1 site added, 1 site removed
    Show site
    • Op0002 20199 · Rui’an, China
    Show 1 removed
    • Op0002 20199 · Rui'an, China
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05067335
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Oct 5, 2021
Start date
Oct 21, 2021
Primary completion
Nov 9, 2023
Completion
Nov 9, 2023
Results posted
Dec 5, 2024
Last update
Sep 28, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion